Does chronic lymphocytic leukemia increase the risk of osteoporosis?



Similar documents
Waldenström Macroglobulinemia: The Burning Questions. IWMF Ed Forum May Morie Gertz MD, MACP

Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014

Supplementary appendix

Malignant Lymphomas and Plasma Cell Myeloma

Chronic Lymphocytic Leukemia. Case Study. AAIM Triennial October 2012 Susan Sokoloski, M.D.

Characteristics and Prognosis of Patients with Richter s Transformation of Chronic Lymphocytic Leukemia: Experience with FDG/PET

Social inequalities impacts of care management and survival in patients with non-hodgkin lymphomas (ISO-LYMPH)

Controversies in the management of patients with PMF 0/1

Leukemias and Lymphomas: A primer

Stem Cell Transplantation

Interesting Case Review. Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA

亞 東 紀 念 醫 院 Follicular Lymphoma 臨 床 指 引

MEDICAL COVERAGE POLICY

Update on Diagnosis and Treatment of Lymphoma

Interesting Case Series. Periorbital Richter Syndrome

Oncology. Objectives. Cancer Nomenclature. Cancer is a disease of the cell Cancer develops when certain cells begin to grow out of control

UNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO Gundersen Health System Center for Cancer and

Summary & Conclusion

Aggressive lymphomas. Michael Crump Princess Margaret Hospital

Thomas de los Reyes PGY 1 Department of Urologic Sciences University of British Columbia. Meet Mr. S

Clinical Policy Guideline

Bone Basics National Osteoporosis Foundation 2013

Kanıt: Klinik çalışmalarda ZYTIGA

MALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010)

Adult Medical-Surgical Nursing H A E M A T O L O G Y M O D U L E : L E U K A E M I A 2

An overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham

Frequency of NHL Subtypes in Adults

6/3/2013. Follicular and Other Slow Growing Lymphomas. Stephen Ansell, MD, PhD Mayo Clinic

Osteoporosis has been identified by the US Surgeon General

Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)

Many people with non-hodgkin lymphoma have found an educational support group helpful. Support

The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma

Hodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla

Things You Don t Want to Miss in Multiple Myeloma

Development of Bone Metastases in Men With Prostate Cancer

Osteoporosis and Vertebral Compression (Spinal) Fractures Fact Sheet

CHILDHOOD CANCER SURVIVOR STUDY Analysis Concept Proposal

Elevated Serum Lactate Dehydrogenase Values in Children with Multiorgan Involvements and Severe Febrile Illness

SECOND PRIMARY BREAST CANCERS FOLLOWING HAEMATOLOGIC MALIGNANCIES A CASE SERIES STUDY FARAH TANVEER PGY 3 DR.MEIR WETZLER DR.

Health Disparities in Multiple Myeloma. Kenneth R. Bridges, M.D. Senior Medical Director Onyx Pharmaceuticals, Inc.

Background. t 1/2 of days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4

Emerging New Prognostic Scoring Systems in Myelodysplastic Syndromes 2012

Bone Disease in Myeloma

Multiple Myeloma Patient s Booklet

Current Multiple Myeloma Treatment Adapted From the NCCN Guidelines

Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC

ASH Review. Wednesday, January 21, Renaissance Cleveland Hotel. 24 Public Square Cleveland, Ohio. 15th Annual

Lymphoma and Chronic Lymphocytic Leukemia Clinical Trials

IF AT FIRST YOU DON T SUCCEED: TRIAL, TRIAL AGAIN

Why discuss CLL? Common: 40% of US leukaemia. approx 100 pa in SJH / MWHB 3 inpatients in SJH at any time

Early mortality rate (EMR) in Acute Myeloid Leukemia (AML)

chronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart

PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA

Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?

Multiple Myeloma Workshop- Tandem 2014

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL VOLUME I RESPONSE ASSESSMENT LEUKEMIA CHAPTER 11A REVISED: OCTOBER 2015

Specific Standards of Accreditation for Residency Programs in Pediatric Hematology/Oncology

UMHS-PUHSC JOINT INSTITUTE

How To Choose A Biologic Drug

Selection of the Optimal Umbilical Cord Blood Unit

New Hampshire Childhood Cancer

Orthopaedic Issues in Adults with CP: If I Knew Then, What I Know Now

Cancer. 9p21.3 deletion. t(12;21) t(15;17)

Childhood Cancer in the Primary Care Setting

A study to Evaluate PPI s effect on vitamin D levels. Rani Hanna M.D., M.S. PGY-3 Joseph Grisanti, MD

Weight Change over Three Decades and the Risk of Osteoporosis in Men

Bone Marrow/Stem Cell Transplant

Leukaemia and lymphoma what s the difference?

Lymphoplasmacytic Lymphoma. Hematology fellows conference 4/12/2013 Christina Fitzmaurice, MD, MPH

A Career in Pediatric Hematology-Oncology? Think About It...

Corporate Medical Policy

Continuing Medical Education Article Imaging of Multiple Myeloma and Related Plasma Cell Dyscrasias JNM, July 2012, Volume 53, Number 7

PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA PROGNOSIS IN ACUTE MYELOID LEUKEMIA

Collect and label sample according to standard protocols. Gently invert tube 8-10 times immediately after draw. DO NOT SHAKE. Do not centrifuge.

Treatment of Myeloma Bone Disease

CHRONIC LYMPHOCYTIC LEUKEMIA

Chemoimmunotherapy resistant follicular lymphoma A single institutional study

Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each

Causes of Anemia in Patients with Heart Failure. Adriaan Voors, MD, PhD, Cardiologist Professor of Cardiology, UMC Groningen, Netherlands

Healthy Aging Lab: Current Research Abstracts

Monoclonal Gammopathy of Undetermined Significance (MGUS) Facts

Falls and Fracture Risk assessment and management

Chapter 5 DASH Your Way to Weight Loss

National Cancer Institute Research on Childhood Cancers. In the United States in 2005, approximately 9,510 children under age 15 will be

Lymphomas after organ transplantation

The 4Kscore blood test for risk of aggressive prostate cancer

Corporate Medical Policy

Update in Hematology Oncology Targeted Therapies. Mark Holguin

PREVENTION OF HCC BY HEPATITIS C TREATMENT. Morris Sherman University of Toronto

Transcription:

Does chronic lymphocytic leukemia increase the risk of osteoporosis? Amrita Desai, MD Internal Medicine Residency Program Adam Olszewski, MD Department of Hematology and Oncology Memorial Hospital of Rhode Island Alpert Medical School of Brown University

Outline Introduction Aims Methodology Results Limitations Conclusions

Chronic Lymphocytic Leukemia (CLL) Most common lymphoproliferative disorder seen in the elderly Incidence rates are 6.7 and 3.6 cases per 100,000 population/year Indolent course Excessive osteoclastic resorption leading to bone demineraliztion Cancer Causes Control 2008; 19:379.

Osteoporosis Skeletal disorder characterized by compromised bone strength predisposing to an increased risk of fractures. Prevalence is estimated to increase from 10 million to >14 million people in 2020 Current medical costs are estimated at $13.7 20.3 billion. Journal of Bone and Mineral Research Volume 22, Issue 3, March 2007

Literature Search Osteoporosis is a known complication: Treated pediatric lymphomas. J Clin Oncol. 1998;16(12):3752-3760. Post- chemotherapy for non-hodgkin lymphoma ASH Annual Meeting Abstracts. 2006;108(11):4607 Unknown whether presence of a bone marrowreplacing process such as CLL is a significant risk factor for osteopenia or osteoporosis

Aims Investigate the prevalence of osteoporosis, osteopenia and compression fractures in patients with CLL treated at MHRI + RIH Identify risk factors for compression fractures Investigate if patients with CLL have increased risk of osteoporosis

Methodology A retrospective cohort study

Inclusion Criteria Case selection: - Patients at RIH and the MHRI Cancer Center - Diagnosis of CLL on the basis of flow cytometry/bone marrow biopsy - Adequate medical information (follow up, physician problem list or radiology evaluations) - Patients with absolute lymphocyte count<5000/mm3 were excluded Controls: - Family Medicine Practice and Internal Medicine patients at MHRI. - ( 2:1)matched on age, gender, race and BMI

Data Collection Demographics: Age at diagnosis and last follow up Ethnicity not available in majority of cases Height, weight and calculated BMI Tobacco use status (current, past, never smoker)

Data Collection Clinical/Laboratory data: Confirmation with flow cytometry CD38 status Available CLL FISH studies Adenopathy Splenomegaly White blood cell count (WBC) Absolute lymphocyte count (ALC) Hemoglobin Platelets Beta-2-microglobulin Lactate dehydrogenase (LDH)

Endpoints: DEXA (dual-energy x-ray absorptiometry) bone density scan results. Evidence of osteoporosis (physician notation, CT scan result) Evidence of osteopenia (physician notation, CT scan result) Evidence of compression fracture (physician notation, report of the CT scan) Composite endpoint (any of the above)

Results cases Controls MHRI (87) RIH (53) MHRI (120) Excluded 27 Included 60 Excluded 17 Included 36 4: ALC < 5000 10: Different diagnosis ( rule out CLL, family history of CLL, LGL leukemia, leukocytosis) 12: inadequate follow up information 1: prisoner 9: ALC < 5000 2: Different diagnosis ( rule out CLL, family history of CLL, LGL leukemia, leukocytosis) 6: inadequate follow up information

Results for: The prevalence of osteoporosis, osteopenia and compression fractures in patients with CLL treated at MHRI Cancer Center and at RIH

Demographics Cases N= 96 Age (median) 71yrs Gender( Females) 48% BMI (median) 26 Absolute Lymphocyte Count (median) 40,850/mm 3 Hemoglobin (mean) LDH (mean) Vitamin D level (mean) Median follow up time 12.4 g/dl 202 IU/L 30.7 ng/ml 2.9 yrs

Prevalence of osteoporosis in CLL patients osteoporosis 12, 11% 96, 89%

Prevalence of osteoporosis +osteopenia in CLL patients osteoporosis 12, 13% 5, 5% osteopenia 79, 82%

Prevalance of compression fractures in CLL patients 7, 7% Compression fractures 96, 93%

Discussion Low prevalence of osteoporosis High prevalence of compression fractures

Results for: Identification of risk factors for compression fractures

Risk factors for Compression Fractures in CLL patients HR CI p Osteopenia/osteoporosis 12.8 95%CI 1.5-109, p=0.004 Anemia 8.9 95%CI 1.1-74 P=0.01 ALC> 100,000/mm3 5.1 95%CI 1.1-23.7 P=0.04

Risk factors for compression fractures in CLL patients

Discussion More disease burden increases risk of compression fracture Need for early screening

Results for: Do patients with CLL have increased risk of osteoporosis?

CT scans Fisher's exact = 0.327

DEXA scans p<0.001

Prevalence of osteoporosis Fisher's exact = 0.107

Compression Fracture odds ratio 1.0, 95%CI 0.32-2.84, p=1.0

Discussion More DEXA scans in controls In some cases men got fewer DEXA scans compared to women Informant bias? More CT scans in cases

Limitations Retrospective study Small cohort Single centre study Paucity of data available on imaging studies

Conclusion The incidence of osteoporosis in CLL patients was 12% The incidence of compression fractures was 7% Compression fractures were higher with osteoporosis/osteopenia and with heavier burden of disease.

References 1. Cabanillas ME, Lu H, Fang S, Du XL. Elderly patients with non-hodgkin lymphoma who receive chemotherapy are at higher risk for osteoporosis and fractures. Leuk Lymphoma. 2007;48(8):1514-1521. 2. Thompson MA, Huen A, Ayers GD, et al. Baseline Osteopenia and Osteoporosis in Untreated Non- Hodgkin's Lymphoma Patients. ASH Annual Meeting Abstracts. 2006;108(11):4607-. 3. Haddy TB, Mosher RB, Reaman GH. Osteoporosis in survivors of acute lymphoblastic leukemia. Oncologist. 2001;6(3):278-285. 4. Nysom K, Holm K, Michaelsen KF, Hertz H, Muller J, Molgaard C. Bone mass after treatment for acute lymphoblastic leukemia in childhood. J Clin Oncol. 1998;16(12):3752-3760. 5. Leone J, Vilque JP, Jolly D, et al. Effect of chlorambucil on bone mineral density in the course of chronic lymphoid leukemia. Eur J Haematol. 1998;61(2):135-139. 6. Molica S, Digiesi G, Antenucci A, et al. Vitamin D insufficiency predicts time to first treatment (TFT) in early chronic lymphocytic leukemia (CLL). Leuk Res. 2011. 7. Shanafelt TD, Drake MT, Maurer MJ, et al. Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood. 2011;117(5):1492-1498. 8. Lecouvet FE, Vande Berg BC, Michaux L, et al. Early chronic lymphocytic leukemia: prognostic value of quantitative bone marrow MR imaging findings and correlation with hematologic variables. Radiology. 1997;204(3):813-818. 9. Asomaning K, Bertone-Johnson ER, Nasca PC, Hooven F, Pekow PS. The association between body mass index and osteoporosis in patients referred for a bone mineral density examination. J Womens Health (Larchmt). 2006;15(9):1028-1034. 10. De Laet C, Kanis JA, Oden A, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int. 2005;16(11):1330-1338.